What does Unipharma do?

Unipharma is a pharmacy in Couvin. Private Limited, started on 27 January 1969, 4 establishments.

What is the address of Unipharma?

The registered office of Unipharma is located at Rue de la Ville 6, 5660 Couvin.

Is Unipharma still active?

Yes. According to the CBE (30 October 2026) Unipharma is active, legal situation “Normale toestand”, started on 27 January 1969.

Is Unipharma registered on Peppol?

Yes, Unipharma is registered on the Peppol network with ID 0208:0406125637.

What is the enterprise number of Unipharma?

The enterprise number of Unipharma is BE0406125637.

When was Unipharma founded?

Unipharma was founded on 27 January 1969.

Who are the directors of Unipharma?

According to the 2025 annual accounts, the directors of Unipharma are: FRANCOIS MONIN, JEAN CHARLES GAYE, LAURENT STAQUET.

Is Unipharma a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 27 January 1969; 5 annual accounts filed, latest fiscal year 2025; 3 directors known from the annual account; 4 establishments in the CBE.

How much profit did Unipharma make in 2025?

Unipharma posted a profit after taxes of € 91,588 in financial year 2025.

What is the revenue of Unipharma?

As a small company, Unipharma is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 1,103,573.

How much does an employee at Unipharma earn?

The average wage cost per full-time employee at Unipharma was € 63,700 in 2025: staff costs of € 923,151 for 14.5 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does Unipharma have?

According to the 2025 annual accounts, Unipharma has 14.5 full-time equivalents (FTE).

Unipharma (Private Limited) - Couvin - BE0406125637

Dossier Unipharma, printed on 30 October 2026 from databakkes.be/en/0406125637/unipharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Tight liquidity NBB

Cash and receivables cover 51 % of short-term debt in 2025; threshold 65 %.

Financials

Financial year 2025

Unipharma from Couvin, company number BE0406125637, closed financial year 2025 with a result of € 91,588 after tax. For that financial year Unipharma recorded a gross margin of € 1.1 million and equity of € 798,860. Compared with financial year 2024, the result moved from € 87,436 to € 91,588. Profitable, and profit is growing. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on August 27, 2026.

What it is worth Growing

€ 798,860

▲ 13% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 91,588

▲ 5% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 148,141

▲ 29% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 724,492.

People and assets in 2025

Full-time equivalents

14.5

▲ 3.7 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 923,151

▲ 26% vs 2024

€ 63,700 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 5,562

▲ 276% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 7 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 960,393

▼ 13% vs 2024

€ 144,900 is repaid this year. At this pace the long-term loan is gone in ≈ 7 years.

Owed to suppliers

€ 240,311

▲ 11% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 134,879

▲ 31% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 940,103 Gross margin 2022: € 940,103 First fiscal year in the series	€ 770,766 Gross margin 2023: € 770,766 ▼ 18% vs 2022 (€ 940,103) Unfavourable step	€ 896,917 Gross margin 2024: € 896,917 ▲ 16% vs 2023 (€ 770,766) Favourable step	€ 1,103,573 Gross margin 2025: € 1,103,573 ▲ 23% vs 2024 (€ 896,917) Favourable step	▲ 23%
Profit after taxes	€ 123,157 Profit after taxes 2022: € 123,157 First fiscal year in the series	€ -33,705 Profit after taxes 2023: € -33,705 ▼ € 156,862 vs 2022 (€ 123,157) Unfavourable step	€ 87,436 Profit after taxes 2024: € 87,436 ▲ € 121,142 vs 2023 (€ -33,705) Favourable step	€ 91,588 Profit after taxes 2025: € 91,588 ▲ 5% vs 2024 (€ 87,436) Favourable step	▲ 5%
Equity	€ 724,190 Equity 2022: € 724,190 First fiscal year in the series	€ 619,836 Equity 2023: € 619,836 ▼ 14% vs 2022 (€ 724,190) Unfavourable step	€ 707,272 Equity 2024: € 707,272 ▲ 14% vs 2023 (€ 619,836) Favourable step	€ 798,860 Equity 2025: € 798,860 ▲ 13% vs 2024 (€ 707,272) Favourable step	▲ 13%
Total debts	€ 1,680,440 Total debts 2022: € 1,680,440 First fiscal year in the series	€ 1,689,805 Total debts 2023: € 1,689,805 ▲ 1% vs 2022 (€ 1,680,440) Unfavourable step	€ 1,789,387 Total debts 2024: € 1,789,387 ▲ 6% vs 2023 (€ 1,689,805) Unfavourable step	€ 1,651,543 Total debts 2025: € 1,651,543 ▼ 8% vs 2024 (€ 1,789,387) Favourable step	▼ 8%
Cash	€ 171,669 Cash 2022: € 171,669 First fiscal year in the series	€ 87,043 Cash 2023: € 87,043 ▼ 49% vs 2022 (€ 171,669) Unfavourable step	€ 114,666 Cash 2024: € 114,666 ▲ 32% vs 2023 (€ 87,043) Favourable step	€ 148,141 Cash 2025: € 148,141 ▲ 29% vs 2024 (€ 114,666) Favourable step	▲ 29%
Land & buildings	€ 78,798 Land & buildings 2022: € 78,798 First fiscal year in the series	€ 63,243 Land & buildings 2023: € 63,243 ▼ 20% vs 2022 (€ 78,798) Unchanged	€ 47,689 Land & buildings 2024: € 47,689 ▼ 25% vs 2023 (€ 63,243) Unchanged	€ 36,203 Land & buildings 2025: € 36,203 ▼ 24% vs 2024 (€ 47,689) Unchanged	▼ 24%
Retained profit	€ 579,174 Retained profit 2022: € 579,174 First fiscal year in the series	€ 545,468 Retained profit 2023: € 545,468 ▼ 6% vs 2022 (€ 579,174) Unfavourable step	€ 632,904 Retained profit 2024: € 632,904 ▲ 16% vs 2023 (€ 545,468) Favourable step	€ 724,492 Retained profit 2025: € 724,492 ▲ 14% vs 2024 (€ 632,904) Favourable step	▲ 14%
Bank debt	€ 1,423,692 Bank debt 2022: € 1,423,692 First fiscal year in the series	€ 1,235,107 Bank debt 2023: € 1,235,107 ▼ 13% vs 2022 (€ 1,423,692) Favourable step	€ 1,101,356 Bank debt 2024: € 1,101,356 ▼ 11% vs 2023 (€ 1,235,107) Favourable step	€ 960,393 Bank debt 2025: € 960,393 ▼ 13% vs 2024 (€ 1,101,356) Favourable step	▼ 13%
Balance sheet total	€ 2,404,631 Balance sheet total 2022: € 2,404,631 First fiscal year in the series	€ 2,309,640 Balance sheet total 2023: € 2,309,640 ▼ 4% vs 2022 (€ 2,404,631) Unchanged	€ 2,496,659 Balance sheet total 2024: € 2,496,659 ▲ 8% vs 2023 (€ 2,309,640) Unchanged	€ 2,450,403 Balance sheet total 2025: € 2,450,403 ▼ 2% vs 2024 (€ 2,496,659) Unchanged	▼ 2%
Employees (FTE)	10.8 Employees (FTE) 2022: 10.8 First fiscal year in the series	11 Employees (FTE) 2023: 11 ▲ 0.2 vs 2022 (10.8) Unchanged	10.8 Employees (FTE) 2024: 10.8 ▼ 0.2 vs 2023 (11) Unchanged	14.5 Employees (FTE) 2025: 14.5 ▲ 3.7 vs 2024 (10.8) Unchanged	▲ 3.7

Key figures of Unipharma, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to Unipharma?

What happened at Unipharma in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Aug 27, 2026 New annual accounts for financial year 2025: profit of € 91,588 (▲ 5% vs 2024). filed late Source: NBB ↗
Mar 1, 2012 New establishment in Charleroi. KBO
Jan 1, 1970 New establishment in Couvin. KBO
Jan 1, 1970 New establishment in Couvin. KBO
Jan 1, 1970 New establishment in Charleroi. KBO
Jan 27, 1969 Start of the company according to the CBE. KBO

In short

From € 123,157 profit in 2022 to € 91,588 profit in 2025.

Paid € 83,736 in corporate taxes since 2022.

Best year ever: 2022, with € 123,157 profit.

On average € 76,100 of value added per employee in 2025.

Original PDFs at the National Bank ↗

Management

FRANCOIS MONIN

JEAN CHARLES GAYE

LAURENT STAQUET

Unipharma

UREEL PHARMACIE 100%

Behind Unipharma are FRANCOIS MONIN, JEAN CHARLES GAYE and LAURENT STAQUET. It owns 100% of UREEL PHARMACIE itself.

Directors

According to the 2025 annual accounts

FRANCOIS MONIN

Director

Also active at: MONIN-DONNEZ, MOMIGNIES PHARMA

JEAN CHARLES GAYE

Director

LAURENT STAQUET

Director

Also active at: PHARMACIE FRANCOIS, JLV Consult, LAVISTA PHARMA

Establishments

Establishment units

Physical locations of this company

Registered office

Rue de la Ville 6

5660 Couvin

2.142.796.514

Faubourg-Saint-Germain 67

5660 Couvin

Active since 1 January 1970

2.142.796.613

Route de Philippeville 146

6010 Charleroi

Active since 1 January 1970

2.208.756.712

Rue Sart-les-Moulins 26

6044 Charleroi

Active since 1 March 2012

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.

All companies at this address →

UREEL PHARMACIE same network

€ 72,612 gross margin · 2025

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0406.125.637

VAT number

BE 0406.125.637

Registered office

Rue de la Ville 6, 5660 Couvin

Names & denominations

Unipharma

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

27 January 1969

Peppol

Active · Active since 20 Nov 2025

Activities · NACE

Detailhandel in farmaceutische producten

Apothekers

Overige rechtskundige dienstverlening

View on CBE Public ↗ Annual accounts (NBB) ↗

Unipharma

Warning lights

Financials

What happened to Unipharma?

Management

Directors

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions